Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. has divulged antibody-drug conjugates (ADCs) comprising antibodies targeting human mucin-17 (MUC17) covalently linked to a cytotoxic drug through a linker reported to be useful for the treatment of cancer.
Avenzo Therapeutics Inc. has obtained IND clearance by the FDA for AVZO-103 (formerly VAC-103), a nectin-4/TROP2 bispecific antibody-drug conjugate (ADC).
CSPC Megalith Biopharmaceutical Co. Ltd. has described antibody-drug conjugates (ADCs) comprising anti-tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) antibodies covalently linked to cytotoxic drugs reported to be useful for the treatment of pancreatic and breast cancer.
Shanghai Ruotuo Biotechnology Co. Ltd. has identified antibody-drug conjugates consisting of antibodies targeting HER2 (erbB2) covalently linked to camptothecin derivatives through a linker reported to be useful for the treatment of cancer.
Cadherin 17 (CDH17), a member of the cadherin family protein involved in intestinal development and cell adhesion, is recognized as a potential therapeutic target in gastrointestinal (GI) cancers. Its tumor-specific overexpression and limited presence in normal tissues offer a favorable profile for the development of selective, targeted treatments.
Pheon Therapeutics Ltd. has identified antibody-drug conjugates comprising antibodies targeting tumor associated antigens covalently linked to cytotoxic drugs through linker reported to be useful for the treatment of cancer.
Systimmune Inc. has synthesized antibody-drug conjugates comprising antibodies targeting tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to cytotoxic drugs through linker reported to be useful for the treatment of cancer.
Mabwell (Shanghai) Bioscience Co. Ltd. announced that its Cadherin-17 (CDH17)-targeting antibody-drug conjugate (ADC), 7MW-4911, has received IND clearance to initiate clinical trials from both the U.S. FDA and China's National Medical Products Administration (NMPA).
Beijing Tide Pharmaceutical Co. Ltd. has divulged nanobody-drug conjugates comprising a nanobody targeting B7 homolog 3 (B7-H3, CD276) covalently bound to exatecan through a linker reported to be useful for the treatment of lung cancer.
Beone Medicines (Beijing) Co. Ltd. has disclosed an antibody-drug conjugate comprising an antibody targeting fibroblast growth factor receptor 2 isoform 2 (FGFR2; FGFR2b) covalently linked to cytotoxic agent through a linker reported to be useful for the treatment of small-cell lung cancer (SCLC) and gastric cancer.
RSS
